Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and ...

Medications like Ozempic and Zepbound work to mimic GLP-1, a hormone that makes you feel full. But there are also ways to ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...